

# CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

## Most recent changes to the CPT<sup>®</sup> Category I New Vaccine Codes Long Descriptor document

- Addition of 8 Category I codes (0004A, 0051A, 0052A, 0053A, 0054A, 0064A, 91305, 91306) accepted by the CPT Editorial Panel. Codes 0004A, 0051A, 0052A, 0053A, 0054A, 0064A, 91305, 91306 and all related references will be published in CPT 2023.
- Guidelines and parenthetical notes are only effective for codes that have received FDA Emergency Use Authorization (EUA) approval.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions may result in gaps in code number sequencing.

The following codes were accepted by the CPT Editorial Panel. Codes 0001A, 0002A, and 91300 are effective December 11, 2020. Codes 0011A, 0012A, and 91301 are effective December 18, 2020. Codes 0031A and 91303 are effective February 27, 2021. Codes 0003A and 0013A are effective August 12, 2021. Codes 0004A, 0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A, 91302, 91304, 91305, and 91306 will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration. \*Note codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, and resequenced codes 0051A, 0052A, 0053A, 0054A, and 0064A will follow code 90474. Resequenced codes 91300, 91301, 91302, 91303, 91304, 91305, and 91306 will precede code 90476.

Code	Long Code Descriptor	Published to AMA website	Effective	Publication
	<p><b>Evaluation and Management Preventive Medicine Services</b></p> <p>► Vaccine/toxoid products, immunization administrations, ancillary studies involving laboratory, radiology, other procedures, or screening tests (eg, vision, hearing, developmental) identified with a specific CPT code are reported separately. For immunization administration and vaccine risk/benefit counseling, see 90460, 90461, 90471-90474, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A. For vaccine/toxoid products, see 90476-90749, 90756-90759, 91300, 91301, 91302, 91303, 91304, 91305, 91306. ◀</p>	<p><b>Revised Guidelines Released to AMA Website</b></p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p>September 3, 2021</p>	<p><b>New and Revised Guidelines Effective</b></p> <p>0001A, 0002A, 91300: December 11, 2020</p> <p>0011A, 0012A, 91301: December 18, 2020</p> <p>0031A, 91303: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p>0004A, 0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A, 91302, 91304, 91305, 91306: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p><b>New and Revised Guidelines Publication</b></p> <p>CPT<sup>®</sup> 2022/2023</p>
	<p><b>Medicine Immunization Administration for Vaccines/Toxoids</b></p> <p>► Report vaccine immunization administration codes (90460, 90461, 90471-90474, 0001A, 0002A, 0003A, 0004A, 0011A,</p>	<p><b>New and Revised Guidelines Released to AMA Website</b></p>	<p><b>New and Revised Guidelines Effective</b></p>	<p><b>New and Revised Guidelines Publication</b></p>

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p><u>0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A</u> in addition to the vaccine and toxoid code(s) <u>(90476-90749, 90756-90759, 91300, 91301, 91302, 91303, 91304, 91305, 91306)</u>.</p> <p>Report codes 90460 and 90461 only when the physician or <u>other</u> qualified health care professional provides face-to-face counseling of the patient/family during the administration of a vaccine <u>other than when performed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines</u>. For immunization administration of any vaccine, <u>other than SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines</u>, that is not accompanied by face-to-face physician or <u>other</u> qualified health care professional counseling to the patient/family/<u>guardian</u> or for administration of vaccines to patients over 18 years of age, report 90471-90474. (See also <b>Instructions for Use of the CPT Codebook</b> for definition of reporting qualifications.) ◀</p>	<p>November 10, 2020 December 17, 2020 January 19, 2021 March 1, 2021 May 4, 2021 July 30, 2021 August 16, 2021 <b>September 3, 2021</b></p>	<p>0001A, 0002A, 91300: December 11, 2020 0011A, 0012A, 91301: December 18, 2020 0031A, 91303: February 27, 2021 0003A, 0012A: August 12, 2021  0004A, 0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A, 91302, 91304, 91305, 91306: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p>CPT<sup>®</sup> 2022/2023</p>
	<p>▶ Report 0001A, 0002A, 0003A, <u>0004A</u>, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, <u>0051A, 0052A, 0053A, 0054A, 0064A</u> for immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only. Each administration code is specific to each individual vaccine product (eg, 91300, 91301, 91302, 91303, 91304, <u>91305, 91306</u>), the dosage schedule (eg, first dose, second dose), and counseling, when performed. The appropriate administration code is chosen based on the type of vaccine and the specific dose number the patient receives in the schedule. For example, 0012A is reported for the second dose of vaccine 91301. Do not report 90460-90474 for the administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines. Codes related to SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine administration are listed in Appendix Q, with their associated vaccine code descriptors, vaccine administration codes, vaccine manufacturer, vaccine name(s), National Drug Code (NDC) Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q. ◀</p> <p>If a significant separately identifiable Evaluation and Management service (eg, new or established patient office or other outpatient services [99202-99215], office or other outpatient consultations [99241-99245], emergency department services [99281-99285], preventive medicine services [99381-99429]) is performed, the appropriate E/M service code should be reported in addition to the vaccine and toxoid administration codes.</p>	<p><b>New and Revised Guidelines Released to AMA Website</b> November 10, 2020 December 17, 2020 January 19, 2021 May 4, 2021 July 30, 2021 August 16, 2021 <b>September 3, 2021</b></p>	<p><b>New and Revised Guidelines Effective</b> 0001A, 0002A, 91300: December 11, 2020 0011A, 0012A, 91301: December 18, 2020 0031A, 91303: February 27, 2021 0003A, 0013A: August 12, 2021  0004A, 0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A, 91302, 91304, 91305, 91306: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p><b>New and Revised Guidelines Publication</b> CPT<sup>®</sup> 2022/2023</p>

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p>A component refers to all antigens in a vaccine that prevent disease(s) caused by one organism (90460 and 90461). Multi-valent antigens or multiple serotypes of antigens against a single organism are considered a single component of vaccines. Combination vaccines are those vaccines that contain multiple vaccine components. Conjugates or adjuvants contained in vaccines are not considered to be component parts of the vaccine as defined above.</p> <p>(For allergy testing, see 95004 et seq)</p> <p>(For skin testing of bacterial, viral, fungal extracts, see 86485-86580)</p> <p>(For therapeutic or diagnostic injections, see 96372-96379)</p>			
90460	<p>Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered</p>			
+90461	<p>each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)</p> <p>(Use 90460 for each vaccine administered. For vaccines with multiple components [combination vaccines], report 90460 in conjunction with 90461 for each additional component in a given vaccine)</p> <p>► (Do not report 90460, 90461 in conjunction with 91300, 91301, 91302, 91303, 91304, <u>91305, 91306</u>, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-907499075690759 are administered at the same encounter) ◀</p>	<p><b>New Parenthetical Note Released to AMA Website</b></p> <p>November 10, 2020</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p><u>September 3, 2021</u></p>	<p><b>New and Revised Parenthetical Note Effective</b></p> <p>91300: December 11, 2020</p> <p>91301: December 18, 2020</p> <p>91303: February 27, 2021</p> <p><u>91302, 91304, 91305, 91306</u>: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p><b>New and Revised Parenthetical Note Publication</b></p> <p>CPT<sup>®</sup> 2022/2023</p>
90471	<p>Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)</p> <p>(Do not report 90471 in conjunction with 90473)</p>			
+90472	<p>each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)</p> <p>(Use 90472 in conjunction with 90460, 90471, 90473)</p> <p>► (Do not report 90471, 90472 in conjunction with 91300, 91301, 91302, 91303, 91304, <u>91305, 91306</u>, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-</p>	<p><b>New Parenthetical Note Released to AMA Website</b></p> <p>November 10, 2020</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p>	<p><b>New and Revised Parenthetical Note Effective</b></p> <p>91300: December 11, 2020</p> <p>91301: December 18, 2020</p> <p>91303: February 27, 2021</p>	<p><b>New and Revised Parenthetical Note Publication</b></p> <p>CPT<sup>®</sup> 2022/2023</p>

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p><del>907499075690759</del> are administered at the same encounter) ◀</p> <p>For immune globulins, see 90281-90399. For administration of immune globulins, see 96365, 96366, 96367, 96368, 96369, 96370, 96371, 96374)</p> <p>(For intravesical administration of BCG vaccine, see 51720, 90586)</p>	<p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>September 3, 2021</p>	<p>91302, 91304, 91305, 91306: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	
90473	<p>Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid)</p> <p>(Do not report 90473 in conjunction with 90471)</p>			
+90474	<p>each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)</p> <p>(Use 90474 in conjunction with 90460, 90471, 90473)</p> <p>▶(Do not report 90473, 90474 in conjunction with 91300, 91301, 91302, 91303, 91304, 91305, 91306, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-<del>907499075690759</del> are administered at the same encounter) ◀</p>	<p><b>New Parenthetical Note Released to AMA Website</b></p> <p>November 10, 2020</p> <p><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>September 3, 2021</p>	<p><b>New and Revised Parenthetical Note Effective</b></p> <p>91300: December 11, 2020</p> <p>91301: December 18, 2020</p> <p>91303: February 27, 2021</p> <p>91302, 91304, 91305, 91306: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p><b>New and Revised Parenthetical Note Publication</b></p> <p>CPT<sup>®</sup> 2022/2023</p>
●0001A	<p>Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose</p>	<p>November 10, 2020</p>	<p>December 11, 2020</p>	<p>CPT<sup>®</sup> 2022</p>
●0002A	<p>second dose</p>	<p>November 10, 2020</p>	<p>December 11, 2020</p>	<p>CPT<sup>®</sup> 2022</p>
●0003A	<p>third dose</p>	<p>July 30, 2021</p>	<p>0001A, 0002A, 91300: December 11, 2020</p> <p>0003A: August 12, 2021</p>	<p>CPT<sup>®</sup> 2022/2023</p>

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

●0004A	booster dose  ▶(Report 0001A, 0002A, 0003A, 0004A for the administration of vaccine 91300)◀ ▶(Do not report 0001A, 0002A, 0003A, 0004A in conjunction with 91305)◀	September 3, 2021	0001A, 0002A: December 11, 2020 0003A: August 12, 2021 0004A: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022/2023
#●0051A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2023
#●0052A	second dose	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2023
#●0053A	third dose	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2023
#●0054A	booster dose ▶(Report 0051A, 0052A, 0053A, 0054A for the administration of vaccine 91305)◀ ▶(Do not report 0051A, 0052A, 0053A, 0054A in conjunction with 91300)◀	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2023
●0011A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose	November 10, 2020	December 18, 2020	CPT <sup>®</sup> 2022
●0012A	second dose	November 10, 2020	December 18, 2020	CPT <sup>®</sup> 2022
●0013A	third dose	August 16, 2021		

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	▶(Report 0011A, 0012A, 0013A for the administration of vaccine 91301) ◀		0011A, 0012A: December 18, 2020  0013A: August 12, 2021	CPT <sup>®</sup> 2022/2023
#●0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose  ▶(Report 0064A for the administration of vaccine 91306) ◀	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2023
●0021A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage; first dose	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022
●0022A	second dose ▶(Report 0021A, 0022A for the administration of vaccine 91302) ◀	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022
●0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage, single dose  ▶(Report 0031A for the administration of vaccine 91303) ◀	January 19, 2021	February 27, 2021	CPT <sup>®</sup> 2022
●0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose	May 4, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022
●0042A	second dose ▶(Report 0041A, 0042A for the administration of vaccine 91304) ◀	May 4, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022
	<b>Vaccines, Toxoids</b>  To assist users to report the most recent new or revised vaccine product codes, the American Medical Association (AMA) currently uses the CPT website, which features updates			

## CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p>of CPT Editorial Panel actions regarding these products. Once approved by the CPT Editorial Panel, these codes will be made available for release on a semiannual (twice a year: July 1 and January 1) basis. As part of the electronic distribution, there is a six-month implementation period from the initial release date (ie, codes released on January 1 are eligible for use on July 1 and codes released on July 1 are eligible for use January 1).</p> <p>The CPT Editorial Panel, in recognition of the public health interest in vaccine products, has chosen to publish new vaccine product codes prior to approval by the US Food and Drug Administration (FDA). These codes are indicated with the <b>✓</b> symbol and will be tracked by the AMA to monitor FDA approval status. Once the FDA status changes to approval, the <b>✓</b> symbol will be removed. CPT users should refer to the AMA CPT website (<a href="http://www.ama-assn.org/go/cpt-vaccine">www.ama-assn.org/go/cpt-vaccine</a>) for the most up-to-date information on codes with the <b>✓</b> symbol.</p>			
	<p>► Codes <del>90476-907499075690759</del>, <u>91300, 91301, 91302, 91303, 91304, 91305, 91306</u> identify the vaccine product only. To report the administration of a vaccine/toxoid <u>other than SARS-CoV-2 (coronavirus disease [COVID-19])</u>, the vaccine/toxoid product codes (<del>90476-907499075690759</del>) must be used in addition to an immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). <u>To report the administration of a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (91300, 91301, 91302, 91303, 91304, 91305, 91306) should be reported with the corresponding immunization administration code (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q.</u> ◀</p> <p>► Do not report <del>90476-907499075690759</del> in conjunction with the SARS-CoV-2 (coronavirus disease [COVID-19]) immunization administration codes 0001A, 0002A, 0003A, <u>0004A</u>, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, <u>0051A, 0052A, 0053A, 0054A, 0064A</u>, unless both a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine/toxoid product and at least one vaccine/toxoid product from <del>90476-907499075690759</del> are administered at the same encounter. ◀</p> <p>► Modifier 51 should not be reported with vaccine/toxoid codes <del>90476-907499075690759</del>, 91300, 91301, 91302, 91303, 91304, <u>91305, 91306</u>, when reported in conjunction with administration codes 90460, 90461, 90471, 90472, 90473, 90474, 0001A, 0002A, 0003A, <u>0004A</u>, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, <u>0051A, 0052A, 0053A, 0054A, 0064A</u>. ◀</p>	<p><b>New and Revised Guidelines Released to AMA Website</b></p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p><b>September 3, 2021</b></p>	<p><b>New and Revised Guidelines Effective</b></p> <p>0001A, 0002A, 91300: December 11, 2020</p> <p>0011A, 0012A, 91301: December 18, 2020</p> <p>0031A, 91303: February 27, 2021</p> <p><u>0004A, 0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A, 91302, 91304, 91305, 91306:</u> Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p><b>New and Revised Guidelines Publication</b></p> <p>CPT® 2022/2023</p>

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	<p>If a significantly separately identifiable Evaluation and Management (E/M) service (eg, office or other outpatient services, preventive medicine services) is performed, the appropriate E/M service code should be reported in addition to the vaccine and toxoid administration codes.</p> <p>To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (eg, Vaccine Adverse Event Reporting System) the exact vaccine product administered needs to be reported. Multiple codes for a particular vaccine are provided in the CPT codebook when the schedule (number of doses or timing) differs for two or more products of the same vaccine type (eg, hepatitis A, Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of administration.</p>			
	<p>The “when administered to” age descriptions included in CPT vaccine codes are not intended to identify a product’s licensed age indication. The term “preservative free” includes use for vaccines that contain no preservative and vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product’s prescribing information (PI) for the licensed age indication before administering vaccine to a patient.</p> <p>Separate codes are available for combination vaccines (eg, Hib-HepB, DTap-IPV/Hib). It is inappropriate to code each component of a combination vaccine separately. If a specific vaccine code is not available, the unlisted procedure code should be reported, until a new code becomes available.</p> <p>►The vaccine/toxoid abbreviations listed in codes 90476-90748, 90756-90759, 91300, 91301, 91302, 91303, 91304, 91305, 91306 reflect the most recent US vaccine abbreviations references used in the Advisory Committee on Immunization Practices (ACIP) recommendations at the time of CPT code set publication. Interim updates to vaccine code descriptors will be made following abbreviation approval by the ACIP on a timely basis via the AMA CPT website (<a href="http://www.ama-assn.org/go/cpt-vaccine">www.ama-assn.org/go/cpt-vaccine</a>). The accuracy of the ACIP vaccine abbreviation designations in the CPT code set does not affect the validity of the vaccine code and its reporting function.</p> <p><u>For the purposes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccinations, codes 0003A, 0013A, and 0053A represent the administration of a third dose when the initial immune response following a two-dose primary vaccine series is likely to be insufficient (eg, immunocompromised patient). In contrast, the booster dose codes 0004A, 0054A, and 0064A represent the administration of a dose of vaccine when the initial immune response to a primary vaccine series was sufficient, but has likely waned over time.</u> ◀</p>	<p><b>New and Revised Guidelines Released to AMA Website</b></p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>March 1, 2021</p> <p>May 4, 2021</p> <p>September 3, 2021</p>	<p><b>New and Revised Guidelines Effective</b></p> <p>91300: December 11, 2020</p> <p>91301: December 18, 2020</p> <p>91303: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p>0004A, 0053A, 0054A, 0064A, 91302, 91304, 91305, 91306: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p><b>New and Revised Guidelines Publication</b></p> <p>CPT<sup>®</sup> 2022/2023</p>



## CPT® Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

	(For immune globulins, see 90281-90399. For administration of immune globulins, see 96365-96375)			
# <del>9</del> 91300	<p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use</p> <p>►(Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A) ◀</p> <p>►Do not report 91300 in conjunction with administration codes 0051A, 0052A, 0053A, 0054A) ◀</p>	<p>November 10, 2020</p> <p>July 30, 2021</p> <p>September 3, 2021</p>	<p>0001A, 0002A, 91300: December 11, 2020</p> <p>0003A: August 12, 2021</p> <p>0004A, 0051A, 0052A, 0053A, 0054A: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p>CPT® 2022/2023</p>

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

#●91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use  ▶(Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A)◀  ▶Do not report 91305 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A)◀	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2023
#●91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use  ▶(Report 91301 with administration codes 0011A, 0012A, 0013A)◀	August 16, 2021	0011A, 0012A: December 18, 2020  0013A: August 12, 2021	CPT <sup>®</sup> 2022/2023
#●91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use  ▶(Report 91306 with administration code 0064A)◀	September 3, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2023
#●91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage, for intramuscular use  ▶(Report 91302 with administration codes 0021A, 0022A)◀	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022
#●91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5 mL dosage, for intramuscular use  ▶(Report 91303 with administration code 0031A)◀	January 19, 2021	February 27, 2021	CPT <sup>®</sup> 2022
#●91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use  ▶(Report 91304 with administration codes 0041A, 0042A)◀	May 4, 2021	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT <sup>®</sup> 2022
90476	Adenovirus vaccine, type 4, live, for oral use			

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

96372	<p><b>Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration</b> <b>Therapeutic, Prophylactic, and Diagnostic Injections and Infusions (Excludes Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration)</b></p> <p>Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular</p> <p>►(For administration of vaccines/toxoids, see 90460, 90461, 90471, 90472, 0001A, 0002A, 0003A, <u>0004A</u>, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>) ◀</p>	<p style="text-align: center;"><b>Revised Parenthetical Note Released to AMA Website</b></p> <p>November 10, 2020</p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p style="background-color: #cccccc;">September 3, 2021</p>	<p style="text-align: center;"><b>Revised Parenthetical Note Effective</b></p> <p>0001A, 0002A: December 11, 2020</p> <p>0011A, 0012A: December 18, 2020</p> <p>0031A: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p><u>0004A</u>, 0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p style="text-align: center;"><b>Revised Parenthetical Note Publication</b></p> <p>CPT<sup>®</sup> 2022/2023</p>
	<p>►<b>Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines</b> ◀</p> <p>►This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (91300, 91301, 91302, 91303, 91304, <u>91305</u>, <u>91306</u>) to their associated immunization administration codes (0001A, 0002A, 0003A, <u>0004A</u>, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u>), manufacturer name, vaccine name(s), 10- and 11-digit National Drug Code (NDC) Labeler Product ID, and interval between doses. These codes are also located in the <b>Medicine</b> section of the CPT code set. ◀</p> <p>►Additional introductory and instructional information for codes 0001A, 0002A, 0003A, <u>0004A</u>, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0042A, <u>0051A</u>, <u>0052A</u>, <u>0053A</u>, <u>0054A</u>, <u>0064A</u> and 91300, 91301, 91302, 91303, 91304, <u>91305</u>, <u>91306</u> can be found in the <b>Immunization Administration for Vaccines/Toxoids and Vaccines, Toxoids</b> guidelines in the <b>Medicine</b> section of the CPT code set. ◀</p>	<p style="text-align: center;"><b>New Appendix Q Released to AMA Website</b></p> <p>November 10, 2020</p> <p style="text-align: center;"><b>Revised Appendix Q Released to AMA Website</b></p> <p>December 17, 2020</p> <p>January 19, 2021</p> <p>May 4, 2021</p> <p>July 30, 2021</p> <p>August 16, 2021</p> <p style="background-color: #cccccc;">September 3, 2021</p>	<p style="text-align: center;"><b>Appendix Q Effective</b></p> <p>0001A, 0002A, 91300: December 11, 2020</p> <p>0011A, 0012A, 91301: December 18, 2020</p> <p>0031A, 91303: February 27, 2021</p> <p>0003A, 0013A: August 12, 2021</p> <p><u>0004A</u>, 0021A, 0022A, 0041A, 0042A, 0051A, 0052A, 0053A, 0054A, 0064A, 91302, 91304, 91305, 91306: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration</p>	<p style="text-align: center;"><b>Appendix Q Publication</b></p> <p>CPT<sup>®</sup> 2022/2023</p>

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines					
Vaccine Code	Vaccine Administration Code(s)	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
# <del>91300</del> ●91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	●0001A (1st Dose) ●0002A (2nd Dose) ●0003A (3rd Dose) ●0004A (Booster)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine / Comirnaty	59267-1000-1 59267-1000-01	1st Dose to 2nd Dose: 21 Days  2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 48-28 or More Days  Booster: Refer to FDA/CDC Guidance
# <del>91305</del> ●91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	#●0051A (1st Dose) #●0052A (2nd Dose) #●0053A (3rd Dose) #●0054A (Booster)	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-1025-1 59267-1025-01	1st Dose to 2nd Dose: 21 Days  2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 28 or More Days  Booster: Refer to FDA/CDC Guidance
# <del>91301</del> ●91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	●0011A (1st Dose) ●0012A (2nd Dose) ●0013A (3rd Dose)	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	1st Dose to 2nd Dose: 28 Days  2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 28 or More Days
# <del>91306</del> ●91306 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	#●0064A (Booster)	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	Refer to FDA/CDC Guidance

## CPT<sup>®</sup> Category I New SARS-CoV-2 Vaccine Codes Long Descriptors

<p># <del>91302</del> ●91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5 mL dosage, for intramuscular use</p>	<p>●0021A (1st Dose) ●0022A (2nd Dose)</p>	<p>AstraZeneca, Plc</p>	<p>AstraZeneca COVID-19 Vaccine</p>	<p>0310-1222-10 00310-1222-10</p>	<p>28 Days</p>
<p># <del>91303</del> ●91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10<sup>10</sup> viral particles/0.5 mL dosage, for intramuscular use</p>	<p>●0031A (Single Dose)</p>	<p>Janssen</p>	<p>Janssen COVID-19 Vaccine</p>	<p>59676-580-05 59676-0580-05</p>	<p>Not Applicable</p>
<p># <del>91304</del> ●91304 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use</p>	<p>●0041A (1st Dose) ●0042A (2nd Dose)</p>	<p>Novavax, Inc</p>	<p>Novavax COVID-19 Vaccine</p>	<p>80631-100-01 80631-1000-01</p>	<p>21 Days</p>